Comment from 1Day Sooner

Summary: 1Day Sooner, an advocacy organization, supports the FDA's request for information by proposing that the FDA leverage and expand its existing Sentinel Initiative infrastructure to support drug repurposing. They argue that the FDA should revive the Catalyst program, expand Sentinel's mandate to include efficacy research, and establish a third-party access program for researchers and non-profits.